Journal
NMR IN BIOMEDICINE
Volume 29, Issue 5, Pages 650-659Publisher
WILEY
DOI: 10.1002/nbm.3509
Keywords
hyperpolarized C-13; angiogenesis; cancer therapy responses; bevacizumab; glioma
Funding
- National Institutes of Health [CA176836, EB009070, AA005965, AA0018681, AA13521-INIA, S10 OD012283, P41 EB015891]
- Department of Defense of the USA [PC100427]
Ask authors/readers for more resources
Hyperpolarized [1-C-13]pyruvate MRS provides a unique imaging opportunity to study the reaction kinetics and enzyme activities of in vivo metabolism because of its favorable imaging characteristics and critical position in the cellular metabolic pathway, where it can either be reduced to lactate (reflecting glycolysis) or converted to acetyl-coenzyme A and bicarbonate (reflecting oxidative phosphorylation). Cancer tissue metabolism is altered in such a way as to result in a relative preponderance of glycolysis relative to oxidative phosphorylation (i.e. Warburg effect). Although there is a strong theoretical basis for presuming that readjustment of the metabolic balance towards normal could alter tumor growth, a robust noninvasive in vivo tool with which to measure the balance between these two metabolic processes has yet to be developed. Until recently, hyperpolarized C-13-pyruvate imaging studies had focused solely on [1-C-13]lactate production because of its strong signal. However, without a concomitant measure of pyruvate entry into the mitochondria, the lactate signal provides no information on the balance between the glycolytic and oxidative metabolic pathways. Consistent measurement of C-13-bicarbonate in cancer tissue, which does provide such information, has proven difficult, however. In this study, we report the reliable measurement of C-13-bicarbonate production in both the healthy brain and a highly glycolytic experimental glioblastoma model using an optimized C-13 MRS imaging protocol. With the capacity to obtain signal in all tumors, we also confirm for the first time that the ratio of C-13-lactate to C-13-bicarbonate provides a more robust metric relative to C-13-lactate for the assessment of the metabolic effects of anti-angiogenic therapy. Our data suggest a potential application of this ratio as an early biomarker to assess therapeutic effectiveness. Furthermore, although further study is needed, the results suggest that anti-angiogenic treatment results in a rapid normalization in the relative tissue utilization of glycolytic and oxidative phosphorylation by tumor tissue. Copyright (c) 2016 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available